Please login to the form below
Siliq
This page shows the latest Siliq news and features for those working in and with pharma, biotech and healthcare.
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Cosentyx, Skyrizi and Tremfya face increasing competition in the psoriasis market however, with a host of other new entrants including Eli Lilly’s Taltz (ixekizumab), Leo/Valeant’s Siliq (brodalumab) and
Latest news
-
Leo Pharma to market AstraZeneca’s brodalumab outside Europe
The treatment also received approval in the US for the same indication at the same time, where it is marketed as Siliq.
-
Novartis claims first place for psoriasis drug Cosentyx in China
It’s the first drug in the IL-17 inhibitor class to be approved in China, ahead of Eli Lilly’s Taltz (ixekizumab) and Bausch Health’s Siliq (brodalumab), and also
-
J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial
Cosentyx was the first IL-17 inhibitor to reach the market and, while it has since been joined by rivals from Eli Lilly (Taltz) and Valeant (Siliq), is well ahead in
-
Sun Pharma passes milestone with novel psoriasis drug approval
IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).
-
AbbVie reports more solid data for would-be psoriasis blockbuster
ixekizumab) and Valeant’s Siliq (brodalumab).
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
